Narrative Review: Ketosis-Prone Type 2 Diabetes Mellitus

Guillermo E. Umpierrez,Dawn Smiley,Abbas E. Kitabchi

DOI: https://doi.org/10.7326/0003-4819-144-5-200603070-00011

IF: 39.2

2006-03-07

Annals of Internal Medicine

Abstract:Several investigators have reported that more than half of African-American persons with new diagnoses of diabetic ketoacidosis have clinical, metabolic, and immunologic features of type 2 diabetes during follow-up. These patients are usually obese, have a strong family history of diabetes, have a low prevalence of autoimmune markers, and lack a genetic association with HLA. Their initial presentation is acute, with a few days to weeks of polyuria, polydipsia, and weight loss and lack of a precipitating cause of metabolic decompensation. At presentation, they have markedly impaired insulin secretion and insulin action, but intensified diabetic management results in significant improvement in beta-cell function and insulin sensitivity sufficient to allow discontinuation of insulin therapy within a few months of follow-up. On discontinuation of insulin therapy, the period of near-normoglycemic remission may last for a few months to several years. The absence of autoimmune markers and the presence of measurable insulin secretion have proven useful in predicting near-normoglycemic remission and long-term insulin dependence in adult patients with a history of diabetic ketoacidosis. This clinical presentation is commonly reported in African and African-American persons but is also observed in Hispanic persons and those from other minority ethnic groups. The underlying mechanisms for beta-cell dysfunction in ketosis-prone type 2 diabetes are not known; however, preliminary evidence suggests an increased susceptibility to glucose desensitization.

medicine, general & internal

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the clinical manifestations, metabolic and immunological characteristics, and pathogenesis of ketosis - prone type 2 diabetes mellitus (KP - T2DM). Specifically, the researchers focus on the following aspects:

1. **Clinical manifestations**: Describe the typical clinical features of KP - T2DM patients, such as obesity, newly diagnosed diabetes, acute onset, polyuria, polydipsia, and weight loss.

2. **Metabolic characteristics**: Analyze the changes in islet β - cell function and insulin sensitivity in these patients after the occurrence of diabetic ketoacidosis (DKA). Studies have shown that in these patients, islet β - cell function is significantly impaired in the short term after DKA, but after intensive treatment, islet β - cell function and insulin sensitivity are restored, and some patients can even stop insulin treatment within a few months.

3. **Immunological characteristics**: Evaluate the autoimmune markers of these patients, such as anti - islet cell antibodies and anti - glutamate decarboxylase antibodies. The results show that these patients usually lack autoimmune markers, which is different from type 1 diabetes patients.

4. **Pathogenesis**: Explore the potential mechanisms leading to islet β - cell dysfunction in KP - T2DM patients. Preliminary evidence suggests that these patients may be more sensitive to islet β - cell desensitization caused by hyperglycemia, which may be due to hyperglycemia toxicity or elevated free fatty acid levels.

5. **Management strategies**: Propose management plans for KP - T2DM patients, including initial DKA treatment, subsequent adjustment of insulin treatment, and the use of oral hypoglycemic drugs. The study found that most patients can stop insulin after a period of insulin treatment and maintain stable blood glucose through diet control or oral drugs.

Through these studies, the paper aims to provide clinicians with a comprehensive understanding of KP - T2DM in order to better diagnose and manage these patients.